Amgen says its experimental drug helped patients lose 20% of weight, Wall Street is not impressed ...Middle East

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight-loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed.Read more...

Read More Details
Finally We wish PressBee provided you with enough information of ( Amgen says its experimental drug helped patients lose 20% of weight, Wall Street is not impressed )

Also on site :

• Your new sofa could be the first sign tariff inflation is hitting home
• Companies turn to AI to navigate Trump tariff turbulence
• Nvidia on AI chip bans, OpenAI gets Jony Ive, and Google's Gemini in cars: Tech news roundup